Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 23 03:24PM ET
29.45
Dollar change
-1.36
Percentage change
-4.41
%
IndexRUT P/E- EPS (ttm)- Insider Own38.91% Shs Outstand66.64M Perf Week-4.91%
Market Cap1.96B Forward P/E- EPS next Y-1.89 Insider Trans2.64% Shs Float40.71M Perf Month-18.31%
Income- PEG- EPS next Q-0.37 Inst Own43.77% Short Float5.77% Perf Quarter-32.47%
Sales- P/S- EPS this Y-40.98% Inst Trans- Short Ratio3.63 Perf Half Y-
Book/sh8.54 P/B3.45 EPS next Y-19.42% ROA- Short Interest2.35M Perf Year-
Cash/sh8.50 P/C3.46 EPS next 5Y- ROE- 52W Range25.77 - 50.23 Perf YTD-20.77%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-41.37% Beta-
Dividend TTM- Quick Ratio57.95 Sales past 5Y-45.67% Gross Margin- 52W Low14.28% ATR (14)3.15
Dividend Ex-Date- Current Ratio57.95 EPS Y/Y TTM- Oper. Margin- RSI (14)40.91 Volatility8.94% 11.40%
Employees61 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price68.20
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q- Payout- Rel Volume1.88 Prev Close30.81
Sales Surprise217.34% EPS Surprise-15.38% Sales Q/Q- EarningsMay 09 BMO Avg Volume647.97K Price29.45
SMA20-11.92% SMA50-19.56% SMA200-23.32% Trades Volume1,109,356 Change-4.41%
Date Action Analyst Rating Change Price Target Change
Feb-20-24Initiated Morgan Stanley Overweight $55
Feb-20-24Initiated Goldman Neutral $42
Feb-20-24Initiated Cantor Fitzgerald Overweight $75
Feb-14-24Initiated H.C. Wainwright Buy $75
May-11-24 10:16AM
May-09-24 01:54PM
08:00AM
May-03-24 11:23AM
Apr-26-24 08:00AM
10:00AM Loading…
Apr-24-24 10:00AM
Apr-11-24 10:02PM
Mar-28-24 08:00AM
Feb-27-24 08:00AM
Jan-30-24 07:00AM
Jan-26-24 04:20PM
Jan-24-24 07:10PM
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Decheng Capital Global Life Sc10% OwnerJan 29 '24Buy19.00400,0007,600,000400,000Jan 31 04:17 PM
Song Hong FangDirectorJan 29 '24Buy19.00263,1574,999,983613,928Jan 31 04:30 PM
Roche Corleen M.CFO & SecretaryJan 29 '24Buy19.002,00038,0002,000Jan 31 04:30 PM
Kasturi VijayChief Medical OfficerJan 29 '24Buy19.001,31524,9851,315Jan 31 04:30 PM